It is a metabolite of etretinate, which was used prior to the introduction of<unk> . Etretinate was discontinued because it had a narrow therapeutic index as well as a long elimination half-life (t1/2=120 days), making dosing difficult. In contrast,<unk> 's half-life is approximately 2 days. However, because<unk>  can be reverse metabolised into etretinate which has an extremely long half-life, women must avoid becoming pregnant for at least three years after discontinuing<unk> . Therefore,<unk>  is generally not recommended for women of child-bearing age with a risk of becoming pregnant.
Acitretin
Lumacaftor
Glucuronide
Liranaftate
Regular insulin
Glibenclamide
Metformin
Insulin degludec